Journal Article
. 2011 Jul; 9:108.
doi: 10.1186/1479-5876-9-108.

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols

Sebastian Attig 1 Leah Price  Sylvia Janetzki  Michael Kalos  Michael Pride  Lisa McNeil  Tim Clay  Jianda Yuan  Kunle Odunsi  Axel Hoos  Pedro Romero  Cedrik M Britten  CRI-CIC Assay Working Group  
  • PMID: 21745365
  •     19 References
  •     12 citations


Background: The introduction of antibody markers to identify undesired cell populations in flow-cytometry based assays, so called DUMP channel markers, has become a practice in an increasing number of labs performing HLA-peptide multimer assays. However, the impact of the introduction of a DUMP channel in multimer assays has so far not been systematically investigated across a broad variety of protocols.

Methods: The Cancer Research Institute's Cancer Immunotherapy Consortium (CRI-CIC) conducted a multimer proficiency panel with a specific focus on the impact of DUMP channel use. The panel design allowed individual laboratories to use their own protocol for thawing, staining, gating, and data analysis. Each experiment was performed twice and in parallel, with and without the application of a dump channel strategy.

Results: The introduction of a DUMP channel is an effective measure to reduce the amount of non-specific MULTIMER binding to T cells. Beneficial effects for the use of a DUMP channel were observed across a wide range of individual laboratories and for all tested donor-antigen combinations. In 48% of experiments we observed a reduction of the background MULTIMER-binding. In this subgroup of experiments the median background reduction observed after introduction of a DUMP channel was 0.053%.

Conclusions: We conclude that appropriate use of a DUMP channel can significantly reduce background staining across a large fraction of protocols and improve the ability to accurately detect and quantify the frequency of antigen-specific T cells by multimer reagents. Thus, use of a DUMP channel may become crucial for detecting low frequency antigen-specific immune responses. Further recommendations on assay performance and data presentation guidelines for publication of MULTIMER experimental data are provided.

Phenotypic analysis of antigen-specific T lymphocytes.
J D Altman, P A Moss, +5 authors, M M Davis.
Science, 1996 Oct 04; 274(5284). PMID: 8810254
Highly Cited.
"MIATA"-minimal information about T cell assays.
Sylvia Janetzki, Cedrik M Britten, +7 authors, Mark M Davis.
Immunity, 2009 Oct 17; 31(4). PMID: 19833080    Free PMC article.
Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop.
Nanette C Schloot, Guido Meierhoff, +7 authors, Timothy Tree.
J Autoimmun, 2003 Nov 20; 21(4). PMID: 14624759
Modeling flow cytometry data for cancer vaccine immune monitoring.
Jacob Frelinger, Janet Ottinger, Cécile Gouttefangeas, Cliburn Chan.
Cancer Immunol Immunother, 2010 Jun 22; 59(9). PMID: 20563720    Free PMC article.
Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions.
Jeffrey G Smith, Heather R Joseph, +5 authors, Michael J Caulfield.
Clin Vaccine Immunol, 2007 Mar 23; 14(5). PMID: 17376862    Free PMC article.
Human T cell responses against melanoma.
Thierry Boon, Pierre G Coulie, Benoît J Van den Eynde, Pierre van der Bruggen.
Annu Rev Immunol, 2006 Mar 23; 24. PMID: 16551247
Highly Cited. Review.
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).
Sylvia Janetzki, Katherine S Panageas, +10 authors, Elispot Proficiency Panel of the CVC Immune Assay Working Group.
Cancer Immunol Immunother, 2007 Aug 28; 57(3). PMID: 17721781    Free PMC article.
T-cell responses of vaccinated cancer patients.
Pierre G Coulie, Pierre van der Bruggen.
Curr Opin Immunol, 2003 Mar 14; 15(2). PMID: 12633661
Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials.
Josephine H Cox, Guido Ferrari, +4 authors, Elispot Collaborative Study Group.
AIDS Res Hum Retroviruses, 2005 Jan 25; 21(1). PMID: 15665646
Mixture modeling approach to flow cytometry data.
Michael J Boedigheimer, John Ferbas.
Cytometry A, 2008 Apr 03; 73(5). PMID: 18383311
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.
Cedrik Michael Britten, Sylvia Janetzki, +9 authors, HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group.
Cancer Immunol Immunother, 2009 Mar 05; 58(10). PMID: 19259668    Free PMC article.
Pattern recognition in flow cytometry.
L Boddy, M F Wilkins, C W Morris.
Cytometry, 2001 Jun 29; 44(3). PMID: 11429770
Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis.
Steven G Smith, Simone A Joosten, +5 authors, Françoise Mascart.
PLoS One, 2009 Dec 04; 4(11). PMID: 19956718    Free PMC article.
Standardization of cytokine flow cytometry assays.
Holden T Maecker, Aline Rinfret, +39 authors, Rafick P Sekaly.
BMC Immunol, 2005 Jun 28; 6. PMID: 15978127    Free PMC article.
Standardization and validation issues of the ELISPOT assay.
Sylvia Janetzki, Josephine H Cox, Neal Oden, Guido Ferrari.
Methods Mol Biol, 2005 Jun 07; 302. PMID: 15937345
Toward the harmonization of immune monitoring in clinical trials: quo vadis?
C M Britten, S Janetzki, +2 authors, A Hoos.
Cancer Immunol Immunother, 2007 Aug 28; 57(3). PMID: 17721782    Free PMC article.
Statistical mixture modeling for cell subtype identification in flow cytometry.
Cliburn Chan, Feng Feng, +3 authors, Thomas B Kepler.
Cytometry A, 2008 May 23; 73(8). PMID: 18496851    Free PMC article.
How many events is enough? Are you positive?
Mario Roederer.
Cytometry A, 2008 Mar 01; 73(5). PMID: 18307257
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.
C M Britten, S Janetzki, +13 authors, M M Davis.
Cancer Immunol Immunother, 2010 Nov 17; 60(1). PMID: 21080166    Free PMC article.
The immuno-oncology framework: Enabling a new era of cancer therapy.
Axel Hoos, Cedrik Britten.
Oncoimmunology, 2012 Jun 28; 1(3). PMID: 22737609    Free PMC article.
Structured reporting of T cell assay results.
Sylvia Janetzki, Axel Hoos, +3 authors, Cedrik M Britten.
Cancer Immun, 2013 Jul 25; 13. PMID: 23882158    Free PMC article.
Immunological Monitoring to Rationally Guide AAV Gene Therapy.
Cedrik Michael Britten, Steffen Walter, Sylvia Janetzki.
Front Immunol, 2013 Sep 26; 4. PMID: 24062741    Free PMC article.
Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.
Sine Reker Hadrup, Dominik Maurer, +6 authors, Cécile Gouttefangeas.
Cytometry A, 2014 Oct 10; 87(1). PMID: 25297339    Free PMC article.
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Mustafa Diken, Sebastian Boegel, +6 authors, Sebastian Kreiter.
Hum Vaccin Immunother, 2014 Dec 09; 10(10). PMID: 25483671    Free PMC article.
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.
Cécile Gouttefangeas, Cliburn Chan, +9 authors, Cedrik M Britten.
Cancer Immunol Immunother, 2015 Apr 10; 64(5). PMID: 25854580    Free PMC article.
Managing Multi-center Flow Cytometry Data for Immune Monitoring.
Scott White, Karoline Laske, +8 authors, Cliburn Chan.
Cancer Inform, 2014 Jan 01; 13(Suppl 7). PMID: 26085786    Free PMC article.
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Weijie Ma, Barbara M Gilligan, Jianda Yuan, Tianhong Li.
J Hematol Oncol, 2016 May 29; 9(1). PMID: 27234522    Free PMC article.
Highly Cited. Review.
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Giuseppe V Masucci, Alessandra Cesano, +10 authors, Magdalena Thurin.
J Immunother Cancer, 2016 Nov 30; 4. PMID: 27895917    Free PMC article.
Highly Cited. Review.
Modulation of CRTh2 expression on allergen-specific T cells following peptide immunotherapy.
Christopher D Rudulier, Elena Tonti, +2 authors, Mark Larché.
Allergy, 2019 May 12; 74(11). PMID: 31077596    Free PMC article.
Optimization in Detection of Antigen-Specific T Cells Through Differentially Labeled MHC Multimers.
Natasja Wulff Pedersen, Karoline Laske, +4 authors, Sine Reker Hadrup.
Cytometry A, 2019 Dec 07; 97(9). PMID: 31808999    Free PMC article.
Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery.
Petra Baumgaertner, Martial Sankar, +9 authors, Alexandre Harari.
Front Immunol, 2021 May 18; 12. PMID: 33995353    Free PMC article.